369 related articles for article (PubMed ID: 15889137)
1. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.
Wang L; Cao O; Swalm B; Dobrzynski E; Mingozzi F; Herzog RW
Gene Ther; 2005 Oct; 12(19):1453-64. PubMed ID: 15889137
[TBL] [Abstract][Full Text] [Related]
2. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.
Fields PA; Kowalczyk DW; Arruda VR; Armstrong E; McCleland ML; Hagstrom JN; Pasi KJ; Ertl HC; Herzog RW; High KA
Mol Ther; 2000 Mar; 1(3):225-35. PubMed ID: 10933938
[TBL] [Abstract][Full Text] [Related]
3. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
[TBL] [Abstract][Full Text] [Related]
4. Technology evaluation: AAV factor IX gene therapy, Avigen Inc.
Fabb SA; Dickson JG
Curr Opin Mol Ther; 2000 Oct; 2(5):601-6. PubMed ID: 11249763
[TBL] [Abstract][Full Text] [Related]
5. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.
Kay MA; Manno CS; Ragni MV; Larson PJ; Couto LB; McClelland A; Glader B; Chew AJ; Tai SJ; Herzog RW; Arruda V; Johnson F; Scallan C; Skarsgard E; Flake AW; High KA
Nat Genet; 2000 Mar; 24(3):257-61. PubMed ID: 10700178
[TBL] [Abstract][Full Text] [Related]
6. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
High KA
Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
[TBL] [Abstract][Full Text] [Related]
7. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects.
Hasbrouck NC; High KA
Gene Ther; 2008 Jun; 15(11):870-5. PubMed ID: 18432276
[TBL] [Abstract][Full Text] [Related]
8. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.
Herzog RW; Fields PA; Arruda VR; Brubaker JO; Armstrong E; McClintock D; Bellinger DA; Couto LB; Nichols TC; High KA
Hum Gene Ther; 2002 Jul; 13(11):1281-91. PubMed ID: 12162811
[TBL] [Abstract][Full Text] [Related]
9. Muscle as a target for supplementary factor IX gene transfer.
Hoffman BE; Dobrzynski E; Wang L; Hirao L; Mingozzi F; Cao O; Herzog RW
Hum Gene Ther; 2007 Jul; 18(7):603-13. PubMed ID: 17594244
[TBL] [Abstract][Full Text] [Related]
10. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
[TBL] [Abstract][Full Text] [Related]
11. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products.
Yuasa K; Yoshimura M; Urasawa N; Ohshima S; Howell JM; Nakamura A; Hijikata T; Miyagoe-Suzuki Y; Takeda S
Gene Ther; 2007 Sep; 14(17):1249-60. PubMed ID: 17581597
[TBL] [Abstract][Full Text] [Related]
12. Persistent expression of canine factor IX in hemophilia B canines.
Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C
Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
[TBL] [Abstract][Full Text] [Related]
13. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.
Yuasa K; Sakamoto M; Miyagoe-Suzuki Y; Tanouchi A; Yamamoto H; Li J; Chamberlain JS; Xiao X; Takeda S
Gene Ther; 2002 Dec; 9(23):1576-88. PubMed ID: 12424610
[TBL] [Abstract][Full Text] [Related]
14. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice.
Petry H; Brooks A; Orme A; Wang P; Liu P; Xie J; Kretschmer P; Qian HS; Hermiston TW; Harkins RN
Gene Ther; 2008 Jan; 15(1):54-60. PubMed ID: 17960164
[TBL] [Abstract][Full Text] [Related]
15. Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy.
Chen J; Wu Q; Yang P; Hsu HC; Mountz JD
Mol Ther; 2006 Feb; 13(2):260-9. PubMed ID: 16324888
[TBL] [Abstract][Full Text] [Related]
16. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.
Manno CS; Pierce GF; Arruda VR; Glader B; Ragni M; Rasko JJ; Ozelo MC; Hoots K; Blatt P; Konkle B; Dake M; Kaye R; Razavi M; Zajko A; Zehnder J; Rustagi PK; Nakai H; Chew A; Leonard D; Wright JF; Lessard RR; Sommer JM; Tigges M; Sabatino D; Luk A; Jiang H; Mingozzi F; Couto L; Ertl HC; High KA; Kay MA
Nat Med; 2006 Mar; 12(3):342-7. PubMed ID: 16474400
[TBL] [Abstract][Full Text] [Related]
17. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
[TBL] [Abstract][Full Text] [Related]
18. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice.
Rivière C; Danos O; Douar AM
Gene Ther; 2006 Sep; 13(17):1300-8. PubMed ID: 16688207
[TBL] [Abstract][Full Text] [Related]
19. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice.
Fields PA; Armstrong E; Hagstrom JN; Arruda VR; Murphy ML; Farrell JP; High KA; Herzog RW
Gene Ther; 2001 Mar; 8(5):354-61. PubMed ID: 11313811
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector.
Liu YL; Mingozzi F; Rodriguéz-Colôn SM; Joseph S; Dobrzynski E; Suzuki T; High KA; Herzog RW
Hum Gene Ther; 2004 Aug; 15(8):783-92. PubMed ID: 15319035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]